

Dates of Meeting: September 29–30, 1997.
Time of Meeting: 9:00 a.m.–recess,
 September 29, 8:30 a.m.–adjournment,
 September 30.

Place of Meeting: II Rockledge Center,
 Room 9104, 6701 Rockledge Drive, Bethesda,
 Maryland 20892.

Agenda: Review and prioritize new research concepts and proposed initiatives developed by the Division of Blood Disease Scientific Research Groups.

Contact Person: Carol H. Letendre, Ph.D., NHLBI/DBDR, II Rockledge Center, 6701 Rockledge Drive, Rm. 10162, MSC 7950, Bethesda, Maryland 20892, (301) 435–0080. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: August 28, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23481 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Special Emphasis Panel (SEP) meeting:

Name of SEP: Neurodevelopmental Battery for the Maternal Lifestyle Study (Teleconference).

Date: September 3, 1997.

Time: 1:00 p.m. (ET)–adjournment.

Place: 61E Building, Room 5E03, 6100 Executive Boulevard, Rockville, MD 20852.

Contact Person: Hameed A. Khan, Ph.D., 61E Building, Rm. 5E03, Rockville, Maryland 20852, Telephone: 301–496–1485.

Purpose/Agenda: To evaluate and review a contract proposal.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussions of this proposal could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposal, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children], National Institutes of Health)

Dated: August 27, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23476 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel meeting:

Name of SEP: ZDK1–GRB–6–J2.

Date: November 19, 1997.

Time: 7:30 p.m.

Place: Indiana University, School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202–5120.

Contact Person: Sharee Pepper, Ph.D., Scientific Review Administrator, Review Branch, NIDDK, Natcher Building, Room 6as–25E, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: (301) 594–7798.

Purpose/Agenda: To review and evaluate grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.847–849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health)

Dated: August 28, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23480 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice

is hereby given of the following National Institute on Drug Abuse (NIDA) Special Emphasis Panel meeting:

Purpose/Agenda: To evaluate and review contract proposals.

Name of Committee: NIDA Special Emphasis Panel (Identification and Analysis of THC, Cocaine, and Other Drugs of Abuse and Their Metabolites in Meconium).

Date: September 8, 1997.

Time: 10:00 a.m.

Place: Contracts Management Branch, National Institute on Drug Abuse, NIH, 5600 Fishers Lane, Room 10–49, Rockville, MD 20857, (Telephone Conference).

Contact Person: Mr. Eric Zatman, Contract Review Specialist, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–42, Rockville, MD 20857, Telephone (301) 443–1644.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Scientist Development, Research Scientist Development, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health)

Dated: August 28, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23482 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Workshop on Thalidomide: Potential Benefits and Risks

Notice is hereby given of the NIH workshop on “Thalidomide: Potential Benefits and Risks,” which will be held September 9–10, 1997, in the Natcher Conference Center of the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892. The conference begins at 8:30 a.m. on September 9 and at 8 a.m. on September 10.

Thalidomide was associated in 1961 with serious human teratogenicity. Its use in the treatment of morning sickness